In a phase II clinical trial, the combination of sorafenib and the AKT inhibitor perifosine induced a noteworthy response rate in cHL patients, though the disease regression was not durable in the majority of these patients, and induced a partial response in one out of four CLL patients included in the study [169]. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.